Pablo Llevenes

Published on 12/10/2025

Seen M, Llevenes P, Kang H, Qiu Y, Ennis C, Chen A, Alexanian S, Steenkamp D, Monti S, Denis GV. Metabolic medications modify prostate cancer progression through exosome reprogramming. bioRxiv. 2025 Dec 10. PMID: 41415378.

Published on 6/3/2025

Qiu Y, Chen A, Yu R, Llevenes P, Seen M, Ko NY, Monti S, Denis GV. Insulin Resistance Increases TNBC Aggressiveness and Brain Metastasis via Adipocyte-Derived Exosomes. Mol Cancer Res. 2025 Jun 03; 23(6):567-578. PMID: 40047645.

Published on 10/12/2024

Llevenes P, Chen A, Lawton M, Qiu Y, Seen M, Monti S, Denis GV. Plasma Exosomes in Insulin Resistant Obesity Exacerbate Progression of Triple Negative Breast Cancer. bioRxiv. 2024 Oct 12. PMID: 39416125.

Published on 5/2/2024

Qiu Y, Chen A, Yu R, Llevenes P, Seen M, Ko NY, Monti S, Denis GV. Insulin Resistance Increases TNBC Aggressiveness and Brain Metastasis via Adipocyte-derived Exosomes. bioRxiv. 2024 May 02. PMID: 38746141.

Published on 12/1/2022

Ennis CS, Llevenes P, Qiu Y, Dries R, Denis GV. The crosstalk within the breast tumor microenvironment in type II diabetes: Implications for cancer disparities. Front Endocrinol (Lausanne). 2022; 13:1044670. PMID: 36531496.

Published on 11/4/2022

Jafari N, Chen A, Kolla M, Pompa IR, Qiu Y, Yu R, Llevenes P, Ennis CS, Mori J, Mahdaviani K, Halpin M, Gignac GA, Heaphy CM, Monti S, Denis GV. Novel plasma exosome biomarkers for prostate cancer progression in co-morbid metabolic disease. Adv Cancer Biol Metastasis. 2022 Dec; 6. PMID: 36644690.

Published on 6/1/2022

Jafari N, Llevenes P, Denis GV. Exosomes as novel biomarkers in metabolic disease and obesity-related cancers. Nat Rev Endocrinol. 2022 Jun; 18(6):327-328. PMID: 35361917.